Trial Profile
A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Monoclonal antibody RFB4 ricin chain A conjugate (Primary)
- Indications B-cell lymphoma
- Focus Adverse reactions
- 05 May 2014 New trial record